KGMU to Host 5th International, 15th National Conference of Indian College of Anaesthesiologist In September, invites Registrations

Uttar Pradesh- King George’s Medical University (KGMU) is set to host its 5th International and 15th National ‘ICACON: Annual National Conference of Indian College of Anaesthesiologists’ from September 12th to 15th, 2024. In this regard, KGMU has issued an advertisement giving details of the conference registration process, fees etc.

The conference has been organised by the Department of Anesthesia and Critical Care of KGMU. The theme of this year’s conference is Outcomes Enhancement in Anesthesia. “We are delighted to invite you to join for the prestigious 5th international and 15th national conference of the Indian College of anesthesiologist (ICACON) this year, set against the backdrop of the vibrant and old charming city of Lucknow with the theme of ‘Outcome Enhancement in Anesthesia’”, the advertisement stated.

REGISTRATION FEE

Interested candidates can register themselves by scanning the QR code mentioned in the advertisement by paying the registration fee given below:

CATEGORY

TILL 31ST MAY

TILL 31ST AUGUST

SEPTEMBER & ON-SPOT REGISTRATION

ICA Membership + Conf. Registration

INR 10500

ICA Membership + PG Student Conf. Registration

INR 7500

ICA Membership

INR 7500

INR 8500

INR

NON-ICA Membership

INR 8500

INR 9500

INR

PG Student

INR 4500

INR 5000

INR

Workshop (13 September 2024) (25 seats in each workshop on a first-come-first-serve basis)

INR 2500/USD 50

INR 2500/USD 50

INR 2500/USD 50

Accompanying Person

INR 3500/USD 100

INR 3500/USD 100

INR 3500/USD 100

CME & Workshop For Paramedics & Nursing Fraternity (12 September 2024)

INR 800

INR 1000

INR 1200

International Delegate

USD 150

USD 175

USD 200

It is to be noted that early attendee of ICACON 2024 can get their ICA members membership at a concessional fee of Rs 3000.

TERMS AND CONDITIONS

1 For PG students, a letter from the HOD/Teacher will be required.

2 Registration cannot be transferred to any other person.

3 Accompanying Persons will not get any certificates.

4 It is mandatory to register for the conference to attend the workshop.

To view the advertisement, click the link below

Powered by WPeMatico

Sun Pharmaceutical Industries Gets CDSCO Panel Nod to Study FDC of Relugolix, Estradiol, Norethindrone Acetate

New Delhi: Rejecting for clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) opined the pharmaceutical major Sun Pharmaceutical Industries to conduct of Phase III clinical trial of the fixed-dose combination (FDC) of Relugolix, Estradiol and Norethindrone Acetate Tablets (40 mg + 1 mg + 0.5 mg) Tablets.

This came after the drug major Sun Pharmaceutical Industries presented the proposal before the committee for CT waiver and the published safety and efficacy data.
The committee did not agree to the clinical trial waiver and the firm was asked to present Phase III CT protocol in continuation with an earlier SEC recommendation dated 19th December 2023.
In continuation with the above, the committee recommended for conducting the Phase III clinical trial as per the protocol presented by the firm.

Relugolix is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication that is used in the treatment of prostate cancer in men and uterine fibroids in women.

Estradiol is used for hormone replacement therapy and post-menopausal osteoporosis. Estradiol is an estrogen (female sex hormone). In women who are undergoing or have attained menopause, it prevents symptoms such as hot flashes, night sweats, and mood swings. It also prevents the bones from becoming porous and fragile (osteoporosis).

Norethisterone is a synthetic second-generation progestin used for contraception, prevention of endometrial hyperplasia in hormone replacement therapy, and in the treatment of other hormone-mediated illnesses such as endometriosis.

At the recent SEC meeting for the Reproductive held on 20th March 2024, the expert panel reviewed the proposal presented by the drug major Sun Pharmaceutical Industries regarding the FDC Relugolix, Estradiol, and Norethindrone Acetate Tablets.
After detailed deliberation, the committee recommended the conducting of a Phase III clinical trial as per the protocol presented by the firm.

Also Read: Eli Lilly Gets CDSCO Panel Nod To Market Mirikizumab for ulcerative colitis in adults

Powered by WPeMatico

Health Bulletin 08/ April/ 2024

Here are the top health news for the day:

NCDRC ruling: Surgeons awarded Rs 9.77 crore; MBBS doctors can now perform hair transplants

Holding that there was no medical negligence during the hair transplant procedure, the National Consumer Disputes Redressal Commission (NCDRC) recently exonerated a Hyderabad-based Hair Transplant Clinic and its two surgeons, who were sued by the patient for a compensation of Rs 9,77,15,000.

Although the patient challenged the qualifications of the doctors to conduct the hair transplant procedure, the top consumer court held that a person having an MBBS degree can perform the procedure of hair transplant, in which vital organs of the body are not affected.

For more information, click on the link below:

Delhi HC urges centre to include Ayurveda, Yoga in Ayushman Bharat

The Delhi High Court has directed the Centre to treat representation as plea seeking the inclusion of Ayurveda, Yoga, and Naturopathy within Ayushman Bharat, the national public health insurance scheme.

A bench of Acting Chief Justice Manmohan and Justice Manmeet PS Arora disposed of the public interest litigation (PIL) after asking the Union Ministry of Ayush to decide the representation expeditiously, news agency PTI reported.

For more information, click on the link below:

OCI candidates now eligible for MBBS, BDS admissions: Karnataka HC

Granting interim relief to a student, the Karnataka High Court bench recently held that students holding Overseas Citizens of India (OCI) cards are to be treated on par with Indian citizens while participating in Online counselling for admission to undergraduate medical and dental courses for 2024-2025.

“…we are of the opinion that this submission can be recorded that the OCI cardholders are to be permitted to participate in Online counseling for admission to undergraduate courses in Medical, Dental and Engineering for the Academic Year 2024-2025 for both Government and Private seats, on par with Indian citizens,” the HC bench of Justices Anu Sivaraman and Anant Ramanath Hegde ordered on April 02, 2024.

For more information, click on the link below:

Uttar Pradesh Government issues guidelines for managing heat-related illnesses

As the state braces for the scorching summer months ahead, the Uttar Pradesh Health Department has taken proactive measures to address the potential risks associated with heat-related illnesses. With temperatures expected to soar, the department has released comprehensive guidelines aimed at mitigating the impact of extreme heat waves on public health.

The guidelines, directed to all District Magistrates and Chief Medical Officers, delineate a strategic framework for coordinated efforts in combating heat-related diseases. Emphasizing inter-departmental collaboration, the directives underscore the importance of proactive measures and community engagement in ensuring public well-being during periods of heightened heat stress.

For more information, click on the link below :

Powered by WPeMatico

Parexel named “Best Contract Research Organization” at 17th Annual ViE Awards

Durham: Parexel, a clinical research
organizations (CROs) providing the full range of Phase I to IV clinical development services, has announced it has been named “Best Contract Research Organization” at the 17th Annual Vaccine
Industry Excellence (ViE) Awards. 

Winners were named across 13 categories, including Best Contract
Research Organization, which recognizes the role of CROs in supporting the development of safe and
effective vaccines. 

“We are honored to be recognized with this year’s ViE Award for Best Contract Research Organization,”
said Amy McKee, MD, Chief Medical Officer & Head of Oncology Center of Excellence. “This
accomplishment reflects the depth of experience and commitment of our cross-functional infectious
disease and vaccine experts and global delivery team to develop leading preventive and therapeutic
vaccines that advance global health. We look forward to our continued collaboration with our
biopharmaceutical customers in this important area to improve patient outcomes.”


Parexel was named from among eight CRO finalists.

A distinguished industry advisory board selected the
company based on its ability to: 
provide a range of services in niche and core therapeutic areas;
demonstrate methods of performance improvement and introduction of new services; ensure attention to
and quality of relationships with clients; reach milestones and final outcomes; and build and maintain
existing and long-term partnerships.

Over the last five years Parexel has conducted more than 225 clinical projects in the infectious disease
and vaccine therapeutic area involving more than 9,150 global sites. Parexel’s Infectious Disease and
Franchise core team is led by Anne Kasmar, MD, MSc, Senior Vice President and Global Therapeutic
Head of Infectious Disease and Vaccines.
The annual ViE Awards, organized by Terrapin, showcase excellence in the global vaccine industry. Parexel was recognized at the ViE Awards
ceremony during the World Vaccine Congress on April 2 in Washington, D.C.

Read also: Peyton Howell to become next CEO of Parexel

Powered by WPeMatico

Medical School Quota Hike: South Korean Govt ready to hold open discussions

Seoul: South Korean Health Minister Cho Kyoo-hong stated on Monday that the government is willing to engage in open discussions regarding the proposed increase in medical school admissions if doctors present a unified and more rational approach.

This comes as about 12,000 trainee doctors nationwide have left their workplaces since February 20 to protest the plan to increase medical school admissions by 2,000 seats next year, causing growing strains on public health services, reports IANS.

While the decision to add 2,000 seats to medical schools was made following scientific research and consultations with the medical community, Cho hinted at the potential for adjusting the magnitude of the quota hike, according to Yonhap.

Also Read:South Korea Doctors Strike: Health Ministry notifies 2 doctors of license suspension

“We intend to engage in sincere discussions with the medical community to persuade them and resolve the dispute,” Cho told a government response meeting.

According to an IANS news agency, “If (doctors) come up with a more reasonable and unified proposal based on scientific grounds and logic, the government can discuss it in an open manner,” he said.

The reform plan has emerged as a hot-button issue for this week’s parliamentary elections, with the ruling People Power Party aiming to regain a majority in the National Assembly.  

Medical Dialogues team recently reported that Medical professors in South Korea are preparing to challenge the government’s decision to increase medical school admissions, citing concerns over their constitutional rights. The move comes amid ongoing disruptions to the country’s medical services, triggered by a plan to add 2,000 new medical students next year to alleviate a shortage of doctors. 

The Medical Professors Association of Korea is scheduled to file the petition with the Constitutional Court before the April 10 general elections against the government’s plan to raise the number of medical students by 2,000 starting next year from the current 3,058 seats to address a shortage of doctors, Yonhap news agency reported.

Powered by WPeMatico

USFDA nod to Bristol Myers Squibb-2seventy bio Abecma for triple-class exposed relapsed or refractory Multiple Myeloma after 2 prior lines of therapy

Princeton: Bristol Myers Squibb and 2seventy bio, Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial.

This approval expands Abecma’s indication, making it available in earlier lines to patients who have relapsed or become refractory after exposure to these three main classes of treatment (triple-class exposed), after two prior lines of therapy. Abecma is administered as a one-time infusion, with a new recommended dose range of 300 to 510 x 106 CAR-positive T cells. 

“Abecma has demonstrated a progression-free survival benefit three times that of standard regimens in relapsed or refractory multiple myeloma, and we are now bringing the promise of cell therapy to patients earlier in their treatment journey,” said Bryan Campbell, senior vice president, Head of Commercial, Cell Therapy, Bristol Myers Squibb. “This approval underpins our commitment to addressing the unmet needs of more patients living with multiple myeloma by improving upon the current treatment paradigm, and we remain steadfast in our pursuit of innovation and advancing cell therapy research to deliver potentially transformative therapies.”

“We are extremely pleased that Abecma will be available to many more patients in the U.S.,” said Chip Baird, chief executive officer, 2seventy bio. “This approval represents another important milestone for patients, for Abecma, and for 2seventy bio as we remain committed to increasing treatment options and working to improve outcomes for patients living with multiple myeloma.”

Despite advances in treatment, multiple myeloma remains an incurable disease characterized by periods of remission and relapse. In early lines of treatment, regimens consisting of combinations of IMiDs, PIs, and anti-CD38 monoclonal antibodies are often used to help manage the disease. Unfortunately, as many patients go on to relapse and/or become refractory to these classes of therapy, more patients are becoming triple-class exposed earlier in their treatment journey. There are limited options for these patients, and triple-class exposed relapsed and/or refractory multiple myeloma is associated with poor outcomes and a median progression-free survival (PFS) of three to five months. In this patient population with high unmet need, Abecma has demonstrated clinically meaningful and statistically significant improvements in PFS (95% CI: 13.3 months vs. 4.4 months [HR: 0.49; p<0.0001]). In addition, Abecma exhibited a well-established safety profile with mostly low-grade cytokine release syndrome and neurotoxicity. No cases of Parkinsonism were reported in the study.

“The results of the KarMMa-3 study are remarkable, especially given the historic outcomes with standard regimens for these patients with relapsed or refractory disease,” said Al-Ola A. Abdallah, M.D., University of Kansas, Clinical Associate Professor, Clinical Director, Hematologic Malignancies and Cellular Therapeutics and chair of U.S. Myeloma Innovations Research Collaborative. “With this approval, these patients now have an opportunity to be treated at an earlier line of therapy with a potentially transformative therapy that offers significantly improved progression-free survival for this difficult-to-treat disease that has had no established treatment approach.”

“To support this approval and future expansions, Bristol Myers Squibb has made continuous investments to increase manufacturing capacity and has shown a consistently high manufacturing success rate of 94% for Abecma in the commercial setting,” the Company stated.

Abecma was recently approved in Japan, Switzerland and the European Union for adult patients with triple-class exposed relapsed and/or refractory multiple myeloma after two prior lines of therapy, making it the only CAR T cell therapy available globally for earlier lines of therapy for patients with triple-class exposed relapsed and/or refractory multiple myeloma. Abecma is also currently approved in Great Britain and Israel for adult patients with triple-class exposed relapsed and refractory multiple myeloma after three or more prior lines of therapy.

The KarMMa-3 trial is a pivotal, Phase 3, open-label, global, randomized, controlled trial evaluating Abecma compared to standard regimens in patients with relapsed and refractory multiple myeloma who have received two to four prior lines of treatment, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and were refractory to the last treatment regimen, with 94% of patients with disease refractory to prior treatment with daratumumab. KarMMa-3 is the only Phase 3 trial to evaluate a CAR T cell therapy in a patient population consisting entirely of triple-class exposed relapsed and refractory multiple myeloma patients. The trial’s patient-centric design allowed for crossover from standard regimens to Abecma upon confirmed disease progression. At the time of the final progression-free survival (PFS) analysis, more than half (56%) of patients in the standard regimens arm crossed over to receive Abecma as a subsequent therapy.

In the study, 254 patients were randomized to receive Abecma and 132 were randomized to receive standard regimens that consisted of combinations that included daratumumab, pomalidomide, and dexamethasone (DPd), daratumumab, bortezomib, and dexamethasone (DVd), ixazomib, lenalidomide, and dexamethasone (IRd), carfilzomib and dexamethasone (Kd) or elotuzumab, pomalidomide and dexamethasone (EPd) chosen based on their most recent treatment regimen and investigator discretion. In the Abecma arm, pretreatment consisted of leukapheresis and optional bridging therapy. The choice to use bridging therapy was at the discretion of the investigator.

At an estimated median duration of follow-up of 15.9 months at the primary PFS analysis, Abecma more than tripled the primary endpoint of PFS compared with standard regimens, with a median PFS of 13.3 months (95% CI: 11.8-16.1) vs. 4.4 months (95% CI: 3.4-5.9), respectively (HR:0.49; 95% CI: 0.38-0.64; p<0.0001), representing a 51% reduction in the risk of disease progression or death with Abecma. Abecma also showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated with Abecma achieving a response, and 39% achieving a complete or stringent complete response. In comparison, less than half of patients (42%) who received standard regimens achieved a response, with 5% experiencing a complete response or stringent complete response. Responses were durable with Abecma, with a median duration of response of 14.8 months (95% CI: 12.0-18.6). In those patients who derived a complete response or better, median duration of response was 20 months (95% CI: 15.8-24.3).

Abecma has exhibited a well-established and consistent safety profile with mostly low-grade cytokine release syndrome (CRS) and neurotoxicity. Among patients who received Abecma in the KarMMa and KarMMa-3 studies (n=349), any grade CRS occurred in 89% of patients, including Grade >3 CRS in 7% of patients, and three cases (0.9%) of Grade 5 CRS reported. The median time to onset of CRS was 1 day (range: 1-27 days), and the median duration of CRS was 5 days (range: 1-63 days). Any grade neurotoxicity occurred in 40% of patients treated with Abecma in the KarMMa and KarMMa-3 studies, including Grade 3 neurotoxicity in 4% of patients, and two cases (0.6%) of Grade 4 neurotoxicity reported. At the safety update for KarMMa-3, one case of Grade 5 neurotoxicity was reported. The median time to onset of neurotoxicity was 2 days (range: 1-148 days), and the median duration of neurotoxicity was 8 days (range: 1-720 days).

Abecma is a CAR T cell therapy that recognizes and binds to BCMA on the surface of multiple myeloma cells leading to CAR T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells. Abecma is being jointly developed and commercialized in the U.S. as part of a Co-Development, Co-Promotion, and Profit Share Agreement between Bristol Myers Squibb and 2seventy bio.

The companies’ broad clinical development program for Abecma includes ongoing and planned clinical studies (KarMMa-2, KarMMa-3, KarMMa-9) for patients with multiple myeloma.

Powered by WPeMatico

NBE To Hold Its 22nd Convocation On May 10th, Details

New Delhi- The National Board of Examination in Medical Sciences (NBEMS) is going to hold its 22nd convocation and awards ceremony on 10th May 2024. This convocation is being conducted for the candidates who have qualified the DNB, DRNB and FNB exit examinations in 2021, 2022 and 2023 sessions.

The convocation will be held at Vigyan Bhawan, New Delhi and will be presided over by Draupadi Murmu, Honorable President of India.

On this, NBE has also issued a notice giving information about the program. The notice states that the registration for the 22nd Convocation has been already started on the official website of NBEMS and all eligible candidates are required to register themselves for the Convocation by 22nd April 2024 by paying the enrollment fee of Rs 2500/-.

At this convocation, degrees and gold medals will be awarded to the following 2021, 2022 and 2023 session candidates who have qualified the DNB, DRNB and FNB exit examinations:

DNB/DrNB EXIT EXAM

FNB EXIT EXAM

December 2021

2022

June 2022

December 2022

April 2023

Meanwhile, the candidates who have been declared as Gold Medal winners have been specially invited to attend this Convocation for the Award Ceremony to receive their Gold Medal winners as well as their Degree Certificates in person. To get the detailed information to attend the award ceremony, specialty-wise, and session-wise list of Gold Medalists has been published on the official website of NBEMS.

Whereas, degree certificates of other eligible candidates will be sent to their correspondence address through speed post within 3 months of the convocation ceremony. However, those candidates are instructed to update their correspondence address online while registering for the Convocation.

Lastly, for any queries, candidates can contact NBEMS through the contact number or write an email, which is mentioned in the notice.

To view the notice, click the link below

Powered by WPeMatico

Ahmedabad hospital vandalized, Two doctors assaulted after death of patient

Ahmedabad: In yet another instance of violence against medical professionals, two doctors of a private hospital at Seventh Heaven on Sarkhej-Makarba headquarters road were allegedly attacked by the kin of a patient who died at the hospital following which one of the doctors filed an FIR in this regard.  

According to the doctor’s statement, the wife of the deceased patient arrived at the hospital with four people. They proceeded to assault the doctors while causing damage to hospital property. Furthermore, the doctors alleged that the assailants made threats of severe consequences before leaving the premises. 

The two doctors in this case have been identified as Dr Uzair Shaikh, the owner of the hospital and Dr Azharuddin Memon, his partner. 

Also read- On-Duty Doctor Allegedly Thrashed By Patient’s Kin At Bhima Bhoi Medical College

The incident took place after the wife of the patient brought him to the hospital’s emergency department after the patient fell unconscious however, Dr Shaikh could not save him with CPR (cardiopulmonary resuscitation) as he claimed that the patient was brought dead at the hospital.  

As per the TOI news report, the patient had been consulting Dr Shaikh for multiple ailments over the past three years. Khan had a complex medical history, including hypertension, heart issues, paralysis, and multiple addictions which complicated his health condition.

According to the FIR, the patient in an unconscious state was rushed to the hospital on April 4 as he suffered from breathlessness and his heart began pumping slowly. However, he was discharged from the hospital on Saturday Afternoon when his health condition improved.

Later on the same day, the patient’s condition worsened, and he was brought back to the hospital unconscious and was declared dead upon arrival. Efforts to revive Khan through CPR were unsuccessful.

After informing the patient’s wife about his death, four of his relatives, aged in their 30s and 40s, arrived at the hospital. They allegedly attacked the two doctors and vandalized hospital property.

Following the incident, Dr Shaikh filed a complaint against the four unknown accused under relevant sections of IPC which included charges- causing hurt, using abusive words, criminal intimidation, causing damage and abutment.

Acting on the complaint, the police registered an FIR and an investigation is underway. 

Also read- Viral Video: BJ Medical College Ophthalmology Resident Doctors Assaulted By Patient’s Kin

Powered by WPeMatico

Medical Bulletin 08/ April/ 2024

Here are the top medical news for the day:

Does protein intake during pregnancy affectinfants’ facial features?

A new study, published in Nature Communications, revealed a novel link between the child’s face and pregnancy lifestyle, specifically protein intake during pregnancy.

A child is expected to share facial features with their parents. However, the face is also influenced by factors beyond genetics, so-called environmental factors. Among those, lifestyle during pregnancy is an essential factor. For example, extensive alcohol consumption during pregnancy can lead to facial abnormalities in the child.

A research team led by Andrei Chagin, Professor of Molecular Medicine, the University of Gothenburg, delved into the mechanisms that control the formation of the facial bone structure during the embryonic phase. The studies revealed that a particular signalling pathway in the cells seemed to play a crucial role in shaping the face.

In the study, researchers performed a genome-wide analysis of RNA transcription from non-coding regulatory elements by sequencing the facial mesenchyme of human embryos and cross-checking the active enhancers thus identified against genes, by GWAS for the normal range human facial appearance. To assess the functional role of the pathways involved, they manipulated both genetically and pharmacologically in mice and zebrafish.Pregnant mice were given diets with high and low protein levels.

The results revealed the signaling pathway, known as mTOR which controls several cell functions, including cell division and cell survival. The researchers found that the mTOR pathway modulates the formation of facial skeletal structures in humans, mice, and zebrafish.The protein levels in the female’s diet were consistent with the activity level of mTOR in the developing face. In newborn offspring, the differences in the face were noticeable, although subtle.

“It is difficult to describe the exact effects, which can be caused by protein content in the diet during human pregnancy. But our data suggest that the mechanism is evolutionarily conserved and, from this perspective, likely serves to increase variability in the feeding apparatus, thus, allowing animals to adapt to various feeding sources in the wild. In mice, we see, for example, an enlarged nasal cavity in the offspring of mice fed a protein-enriched diet and a slightly elongated jaw in mice where the mother has eaten a low-protein diet,” said Andrei Chagin.

Reference:Xie, M., et al. (2024). The level of protein in the maternal murine diet modulates the facial appearance of the offspring via mTORC1 signaling. Nature Communications. doi.org/10.1038/s41467-024-46030-3.

Intermittent fasting may protect gut health as we age, finds study

In a new study presented at the annual meeting of the American Physiology Summit, researchers from the Arizona College of Osteopathic Medicine at Midwestern University in Downers Grove reported that intermittent fasting may also help protect the gastrointestinal system — mainly the small intestine — as it ages.

Intermittent fasting is a timed schedule of eating at certain periods of time and then withholding food for an extended duration, a period known as fasting, when a person abstains from eating.Some of the more popular patterns of intermittent fasting include time-restrictive eating, where the fast lasts 12, 14, or 16 hours, and the eating period stretches over the remaining hours of the day, or the 5:2 method, where a person consumes only 500 calories for 2 days of the week and then eats normally for the remaining 5 days.In addition to weight loss, recent studies show that intermittent fasting may offer other health benefits, such as protection against type 2 diabetes, cardiovascular disease, and cancer, as well as against gastrointestinal issues, such as inflammatory bowel disease (IBD)Trusted Source and ulcerative colitis.

In the study, researchers used a mouse model that they had genetically modified to accelerate ageing. One group of mice had food available at all times, while the other group only had access to food during alternating 24-hour cycles. They focused on a specific part of the small intestine called the jejunum, responsible for continuing food digestion and absorbing nutrients and water from food so it can be used in other areas of the body.

After 8 months, scientists found that the mice on the fasting plan gained less weight and had structural changes in their small intestines associated with better glucose control and decreased inflammation. They also observed that improvements in the health and appearance of the small intestine were more pronounced in female mice than in male mice.However, scientists found that the impact of intermittent fasting on blood sugar levels was stronger in male mice than in female mice.

“Our study suggests that intermittent fasting is a beneficial dietary practice to control weight gain, improve blood glucose levels, and promote positive intestinal effects by reducing inflammation and oxidative stress while altering intestinal structure,” said Spencer Vroegop, a second-year student at the Arizona College of Osteopathic Medicine at Midwestern University and first author of this study. “Our study suggests that an intermittent fasting diet may help prevent these age-related changes by returning the jejunum to a ‘younger’ version of itself.”

Reference: Annual Meeting: The American Physiology Summit

Does exercise help prevent age-related issues?

A recent animal study from researchers in the Department of Internal Medicine at the University of Utah in Salt Lake City investigated the role of DNA damage in blood vessels and the ageing cardiovascular system.

The findings will be presented at The American Physiology Summit — the annual meeting of the American Physiological Society.

Our risk of heart disease and other cardiovascular problems increases as we age. Commonly, this is due to atherosclerosis — a build-up of fatty substances on the lining of blood vessels.As these plaques grow, they narrow the vessels, increasing the risk of cardiovascular events like heart attacks or strokes. Previous research has shown that exercise can significantly reduce the risk of atherosclerosis. Even exercise during older age can slow plaque buildup and improve cardiovascular outcomes.

In the study, researchers observed 15 male mice for 4 weeks in a cage with a running wheel. They assigned them to three categories based on how far they ran each day:high-running, moderate-running and low-running.At the end of the study, the scientists collected tissue from the animals’ aortas — the blood vessel that carries blood from the heart. They looked at different sections of the aorta, which are exposed to varying levels of shear stress.In particular, they focused on two types of cells:endothelial cells, which line the inside of blood vessels, vascular smooth muscle cells, which sit within blood vessel walls. Further, they evaluated the cells’ DNA damage and assessed how well their telomeres functioned.

The analysis showed that increased physical activity was associated with less DNA damage and better telomere function in endothelial cells but not vascular smooth muscle cells. Furthermore, this study added to the growing evidence that exercise may benefit health by defending against DNA damage and protecting telomere function.

“By revealing the varied responses of aortic regions experiencing different blood flow patterns and cell types to aerobic exercise,this research provides a firm ground on a detailed and customized approach to interventions for cardiovascular health,” said Jisok Lim, PhD, a postdoctoral fellow at the University of Utah and lead author of the study.

Reference:Late-life aerobic exercise reverses DNA and telomere dysfunction in non-atheroprone aortic regions with advanced age; Annual Meeting: The American Physiology Summit

Powered by WPeMatico

Kozhikode MCH ICU Sexual Assault Case: Nursing Officer rejoins duty

Kozhikode: Senior nursing officer P B Anitha resumed her duties at Kozhikode Government Medical College Hospital (GMCH) on Sunday, marking the end of her sit-in protest outside the hospital. Her demonstration was prompted by the hospital’s refusal to reinstate her despite a High Court directive.  

Anitha alleged that this denial came as a result of support to a sexual assault survivor in the ICU case. Anitha had decided to continue with a sit-in protest until the High Court’s order to reinstate her was implemented. However, reports emerged of the government’s intention to appeal against the ruling, further complicating the situation. Previously transferred to Idukki from Kozhikode, Anitha’s ordeal began when she advocated for the survivor, reports The Daily. 

The court’s decision on April 1 mandated her reinstatement, yet the hospital authorities failed to comply, citing procedural hurdles. The Director of Medical Education (DME) stated that only a government directive could authorize Anitha’s return. Now, finally, after her protest, the government has reinstated her. However, the order pointed out that the appointment would be subject to the High Court’s verdict in its review petition.

Despite being allowed back to work, Anitha remains resolute in pursuing her contempt of court petition against the government. This determination stems from the government’s review petition against the High Court’s directive to reinstate her. Talking to Manorama News, she stated, “I respect the government’s stance. I hope the court’s judgement on the government’s review petition will favour my appointment. I got six more years in service. I need to fight all the challenges till my retirement.”

The incident took place on March 18, 2023, when a young woman, recuperating from surgery in the Intensive Care Unit (ICU), was subjected to sexual abuse by a male attendant. Following the assault, six female hospital employees, in an attempt to coerce the survivor, threatened her to retract her complaint. Anitha promptly reported this misconduct to the college authorities, resulting in the suspension of the six employees.

However, repercussions followed for Anitha and other nursing officials, as they were subsequently transferred from Kozhikode as punitive measures for their cooperation with the special inquiry commission and law enforcement agencies, reports The Daily. 

Also Read: HC relief: Doctor accused of abetting former fiance’s suicide over alleged dowry demand allowed to rejoin MS Orthopaedics course

Powered by WPeMatico